BMS registers observational LUNIS study of Reblozyl in lower-risk MDS patients in Germany
Bristol-Myers Squibb's new non-interventional study will track transfusion-dependent lower-risk MDS patients starting first-line luspatercept in German clinical practice.
Bristol-Myers Squibb's filing activity for the week centers on a single newly posted observational study.
- Bristol-Myers Squibb is the lead sponsor of NCT07752121, called LUNIS, an observational study of first-line luspatercept (Reblozyl) in adults with very low, low, or intermediate risk myelodysplastic neoplasms requiring red blood cell transfusions who are prescribed luspatercept as part of routine medical care.1 The study is recruiting with an estimated enrollment of 190 participants, and the primary outcome is the percentage of participants achieving red blood cell transfusion independence for at least 8 consecutive weeks, measured up to Week 24.1 Participants will be followed for up to 2 years, with data collected on transfusion-free periods, hemoglobin changes, quality of life, and safety outcomes in routine clinical practice in Germany.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.